Form 4: Cargo Therapeutics Director Acquires Stock Options

Krishnan Viswanadhan, a director at Cargo Therapeutics, acquired stock options for 23,742 shares on June 4, 2024.

Summary

• Krishnan Viswanadhan, a director of CARGO Therapeutics, Inc., filed a Form 4 on June 6, 2024.
• The form reports a transaction that occurred on June 4, 2024, where Viswanadhan acquired stock options for 23,742 shares of Common Stock.
• The exercise price of the stock options is $19.17.
• The options vest on the earlier of June 4, 2025, or the next Annual Meeting following June 4, 2024, contingent upon continued service to the Issuer.
• The expiration date for the options is June 3, 2034.
• Following the transaction, Viswanadhan directly owns derivative securities for 23,742 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options to a director is generally viewed as a positive sign, indicating confidence in the company's future. However, it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon the Reporting Person's continued service to the Issuer, incentivizing continued involvement with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year or the next annual meeting is fairly typical.
• The exercise price is set at $19.17.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates